WALTHAM, Mass. — Thermo Fisher Scientific Inc. (NYSE: TMO) announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to support the PRECISE-SG100K study, a large-scale national biobank initiative focused on advancing population-level proteomics research.
The partnership reflects growing global investment in biobank programs that aim to use proteomics and multi-omic data to better understand disease biology, with the goal of improving early detection, prevention, and personalized treatment strategies.
“Proteomics at population scale represents one of the most powerful opportunities to understand disease in real time across the full continuum of health,” said Marc N. Casper, chairman and chief executive officer of Thermo Fisher. “By combining our deep scientific expertise with industry-leading technologies, we are helping national health leaders translate complex biological data into insights that can fundamentally transform human health.”
As part of the PRECISE-SG100K program, Thermo Fisher will deploy an integrated proteomics approach combining its Olink Proximity Extension Assay platforms with its Orbitrap Astral mass spectrometry system. The company said these technologies, alongside Seer’s Proteograph platform, will enable both targeted protein measurement and broader discovery-based proteomics at scale.
The study is designed to analyze proteomic and clinical data from a large, longitudinal population cohort, allowing researchers to identify biological patterns, improve patient stratification, and generate insights that can be translated into clinical applications. Thermo Fisher said integrating multiple proteomic technologies strengthens reproducibility and supports the development of regulatory-grade evidence.
“National biobank initiatives require technologies that deliver both breadth and precision,” said Karen Nelson, Ph.D., chief scientific officer at Thermo Fisher. “By integrating our differentiated technologies, we are enabling high-confidence biomarker identification and accelerating the path to translational application. This complementary strategy sets a new standard for multi-proteomics analysis and empowers researchers to see true disease biology with speed and at scale.”
The collaboration also allows researchers to compare findings with data from other global population-scale studies, expanding opportunities for validation and accelerating the translation of discoveries into clinical use.
Thermo Fisher said it has extensive experience supporting large-scale biobank and omics initiatives worldwide, including projects such as the UK Biobank Pharma Proteomics Project, Finland’s FinnGen study, and the MyCode Community Health Initiative in the United States. Together, these efforts encompass analysis of more than one million samples.
“By applying this integrated proteomics approach across our national cohort, we gain a dynamic view of disease biology within Singapore’s uniquely diverse population,” said John Chambers, Ph.D., chief scientific officer at PRECISE and lead principal investigator of the PRECISE-SG100K study. “This model strengthens our ability to uncover early molecular signals of disease, understand risk across different global communities and generate insights that can inform the future of population health.”
The PRECISE-SG100K study is supported by Seer, Inc. as a research collaboration partner, while Novogene is providing laboratory services for sample processing and data generation.
